HC Wainwright Reaffirms “Buy” Rating for PolyPid (NASDAQ:PYPD)

HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research note released on Wednesday, Benzinga reports. The firm currently has a $14.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.

PolyPid Price Performance

PolyPid stock opened at $4.94 on Wednesday. PolyPid has a one year low of $3.57 and a one year high of $13.23. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.17. The business has a fifty day moving average price of $4.95 and a 200-day moving average price of $5.02.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.17) by ($1.80). As a group, equities analysts anticipate that PolyPid will post -3.72 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. acquired a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid accounts for approximately 1.8% of Rosalind Advisors Inc.’s holdings, making the stock its 20th largest position. Rosalind Advisors Inc. owned approximately 8.67% of PolyPid as of its most recent SEC filing. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.